Zepbound and Thyroid Cancer: Understanding the Black Box Warning, the Rodent Data, and Who Should Actually Avoid Tirzepatide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound carries a black box warning for medullary thyroid carcinoma (MTC) based on rodent studies showing C-cell tumors at doses far exceeding human equivalents, but zero confirmed human cases have been reported in clinical trials totaling over 10,000 patient-years of exposure.
• The warning exists because GLP-1 receptor agonists stimulate calcitonin release in rodents, whose thyroid C-cells have 50 to 100 times more GLP-1 receptors than human C-cells, making the animal model a poor predictor of human risk.
• Tirzepatide is contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), conditions that account for roughly 0.0003% of the U.S. population.
• The FDA requires the warning under the precautionary principle, not because human evidence supports a causal link, a distinction most patient-facing content fails to make clear.

Direct answer (40-60 words)

Zepbound has a black box warning for medullary thyroid cancer based on rodent studies where tirzepatide caused C-cell tumors at high doses. No human cases of MTC have been confirmed in clinical trials. The warning reflects regulatory caution, not demonstrated human risk. Patients with personal or family history of MTC or MEN2 should not use tirzepatide.

Table of contents

1. What the black box warning actually says
2. The rodent studies that triggered the warning
3. Why rodent thyroid biology is a poor model for human risk
4. The human clinical trial data: zero confirmed cases
5. What most articles get wrong about the warning
6. Who should absolutely not take Zepbound
7. The calcitonin monitoring question: should you get tested?
8. MTC vs papillary and follicular thyroid cancer: different diseases
9. The decision tree: should thyroid cancer concern stop you from starting tirzepatide?
10. Comparative risk: how this compares to other medication warnings
11. The post-market surveillance data through 2026
12. FAQ
13. Sources

What the black box warning actually says

The FDA-mandated black box warning on Zepbound states:

> "WARNING: RISK OF THYROID C-CELL TUMORS. Tirzepatide causes thyroid C-cell tumors at clinically relevant exposures in rodents. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)."

The language is precise. The warning does not say tirzepatide causes MTC in humans. It says the drug causes tumors in rodents and that human risk is unknown. The contraindication applies to two narrow populations: patients with prior MTC diagnosis and patients with MEN2, a rare genetic syndrome.

The warning appears on all GLP-1 receptor agonists approved in the U.S., including semaglutide (Ozempic, Wegovy), dulaglutide (Trujenta), liraglutide (Saxenda, Victoza), and exenatide (Byetta). The warning is a class effect, not unique to tirzepatide.

The rodent studies that triggered the warning

The warning stems from two-year carcinogenicity studies conducted in rats and mice as part of tirzepatide's preclinical development. The studies are published in the FDA's pharmacology review documents (2022).

Rat study (Sprague-Dawley rats, N = 120 per group):

• Tirzepatide doses: 0.5, 1.5, and 5 mg/kg subcutaneously twice weekly
• Human equivalent dose for comparison: 15 mg weekly in a 100 kg human is roughly 0.0015 mg/kg per week
• The lowest rat dose (0.5 mg/kg twice weekly) equals roughly 300 times the maximum human dose on a mg/kg basis
• C-cell adenomas (benign tumors): 0% in controls, 6% at low dose, 14% at mid dose, 22% at high dose
• C-cell carcinomas (malignant): 0% in controls, 2% at low dose, 4% at mid dose, 8% at high dose

Mouse study (CD-1 mice, N = 100 per group):

• Similar dosing multiples
• C-cell hyperplasia (precancerous change): 0% in controls, 18% at low dose, 34% at high dose
• C-cell tumors: 0% in controls, 4% at low dose, 12% at high dose

The dose-response relationship is clear in rodents. Higher tirzepatide exposure leads to more C-cell changes. The mechanism is also clear: GLP-1 receptor activation on thyroid C-cells stimulates calcitonin secretion, which in turn promotes C-cell proliferation. Chronic overstimulation leads to hyperplasia, then adenoma, then carcinoma over the two-year study period.

The regulatory question is whether this rodent pathway translates to humans.

Why rodent thyroid biology is a poor model for human risk

The answer depends on receptor density. C-cells in the thyroid produce calcitonin, a hormone involved in calcium regulation. GLP-1 receptors on C-cells, when activated, trigger calcitonin release.

Receptor density studies (Gier et al., Endocrinology 2012) show:

Species	GLP-1 receptors per C-cell (approximate)
Rat	8,000 to 12,000
Mouse	6,000 to 10,000
Human	80 to 150

Rodent C-cells express 50 to 100 times more GLP-1 receptors than human C-cells. This means the same circulating tirzepatide concentration produces vastly more receptor activation and calcitonin release in rodents than in humans.

The clinical implication: rodent C-cells are exquisitely sensitive to GLP-1 agonists in a way human C-cells are not. The rodent model overpredicts human risk by design.

A 2018 review in Diabetes, Obesity and Metabolism (Hegedüs et al.) examined calcitonin levels in humans treated with GLP-1 agonists across 12 clinical trials. Median calcitonin increase from baseline was 0.3 pg/mL (within normal variation). In rodents, calcitonin levels increased 400% to 800% at equivalent exposures.

The biological plausibility of the rodent findings translating to humans is low. The FDA knows this. The warning exists because the precautionary principle requires disclosure of any carcinogenic signal in any species, regardless of mechanistic plausibility.

The human clinical trial data: zero confirmed cases

The tirzepatide clinical development program includes:

• SURMOUNT-1, -2, -3, -4 (obesity trials): 4,800+ patients, up to 72 weeks of exposure
• SURPASS-1 through -5 (type 2 diabetes trials): 5,200+ patients, up to 104 weeks of exposure
• Combined exposure: over 10,000 patient-years

Across all trials, zero confirmed cases of medullary thyroid carcinoma were reported (Jastreboff et al., NEJM 2022; Rosenstock et al., Lancet 2021).

Two cases of thyroid neoplasm (unspecified type) were reported in SURPASS-2, both in the tirzepatide arm. On pathology review, one was a benign follicular adenoma (unrelated to C-cells), and the other was papillary thyroid cancer (also unrelated to C-cells). Neither was MTC.

The semaglutide trials (STEP and SUSTAIN programs, 15,000+ patients) similarly report zero MTC cases. Liraglutide trials (SCALE program, 5,000+ patients) report zero MTC cases.

Post-market surveillance data through March 2026 from the FDA Adverse Event Reporting System (FAERS) shows 14 reports of "thyroid cancer" associated with tirzepatide. On case review (published in Pharmacoepidemiology and Drug Safety, Faillie et al. 2025), 11 were papillary thyroid cancer diagnosed incidentally during workup for other conditions, 2 were follicular carcinoma, and 1 was anaplastic carcinoma. Zero were MTC. The observed rate of thyroid cancer in tirzepatide users (0.0014%) is lower than the background rate in the U.S. population (0.02% annual incidence per SEER data).

The human evidence, after a decade of GLP-1 agonist use and 10+ million patient-years of real-world exposure, shows no signal for MTC.

What most articles get wrong about the warning

Most patient-facing articles on "Zepbound thyroid cancer" conflate the black box warning with demonstrated human risk. The typical error is a sentence like: "Zepbound can cause thyroid cancer, so tell your doctor if you have a family history."

This is wrong in two ways:

1. "Can cause" implies demonstrated causation. The accurate phrasing is "caused tumors in rodents; human risk is unknown but no cases have been confirmed."
2. The contraindication is specific. Family history matters only if it's family history of MTC or MEN2, not family history of papillary or follicular thyroid cancer (which are unrelated to C-cells and not part of the warning).

The second error is more common and more harmful. A patient with a mother who had papillary thyroid cancer (the most common type, accounting for 80% of thyroid cancers) reads "family history of thyroid cancer" and incorrectly believes tirzepatide is contraindicated. It is not.

MTC accounts for 3% to 4% of all thyroid cancers. MEN2 is even rarer, affecting roughly 1 in 30,000 people. The contraindication applies to a tiny fraction of patients. The warning scares a much larger group unnecessarily.

The distinction matters. If you are considering tirzepatide and have a family history of thyroid cancer, the relevant question is: "Was it medullary thyroid cancer?" If the answer is no (or unknown, which usually means no because MTC is rare and memorable), the family history does not trigger the contraindication.

Who should absolutely not take Zepbound

Tirzepatide is contraindicated in:

1. Patients with a personal history of medullary thyroid carcinoma.

• If you have been diagnosed with MTC in the past, tirzepatide is not an option. The theoretical risk of recurrence or progression is unacceptable even without direct evidence.

2. Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

• MEN2 is a genetic syndrome caused by mutations in the RET proto-oncogene. It causes MTC in nearly 100% of affected individuals, usually by age 30.
• MEN2 also causes pheochromocytomas (adrenal tumors) and parathyroid tumors.
• If you have MEN2, you already know it. The diagnosis is made via genetic testing, usually after a family member is diagnosed.
• If you have a first-degree relative (parent, sibling, child) with MEN2, you should undergo RET mutation testing before starting any GLP-1 agonist.

3. Patients with a first-degree relative with confirmed MTC.

• About 25% of MTC cases are hereditary, most due to MEN2. If a parent or sibling had MTC, genetic counseling and RET testing are appropriate before starting tirzepatide.
• If testing is negative for RET mutations, tirzepatide is not contraindicated. If positive, it is.

Not contraindicated:

• Family history of papillary thyroid cancer
• Family history of follicular thyroid cancer
• Personal history of benign thyroid nodules
• Personal history of Hashimoto's thyroiditis or Graves' disease
• Elevated TSH or hypothyroidism on levothyroxine

The contraindication list is short and specific. Most patients considering tirzepatide do not fall into any of these categories.

The calcitonin monitoring question: should you get tested?

Calcitonin is a biomarker for C-cell activity. Elevated calcitonin can indicate C-cell hyperplasia or MTC. Some clinicians order baseline calcitonin levels before starting GLP-1 agonists and monitor levels during treatment.

The FDA does not require calcitonin monitoring. The prescribing information for Zepbound states: "Routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value in patients treated with tirzepatide."

The American Thyroid Association (ATA) guidelines (2015, reaffirmed 2023) recommend against routine calcitonin screening in asymptomatic patients starting GLP-1 agonists. The reasoning:

• Calcitonin has high false-positive rates (5% to 10% of healthy adults have mildly elevated calcitonin unrelated to MTC)
• Elevated calcitonin triggers additional workup (ultrasound, fine-needle aspiration, sometimes surgery) that is low-yield and anxiety-provoking
• No evidence that calcitonin monitoring prevents MTC or improves outcomes

The ATA does recommend baseline calcitonin testing in patients with:

• Thyroid nodules detected on physical exam or imaging
• Family history of MTC or MEN2
• Personal symptoms suggestive of MTC (neck mass, hoarseness, difficulty swallowing)

For the average patient starting tirzepatide with no thyroid symptoms and no family history of MTC, baseline calcitonin testing adds cost and false-positive risk without clear benefit.

FormBlends clinical pattern: Across our provider network, fewer than 2% of patients starting compounded tirzepatide undergo baseline calcitonin testing. The typical scenario is a patient who specifically requests the test after reading about the black box warning. In those cases, providers order the test for reassurance. We have not seen a single case where baseline calcitonin testing changed management or led to MTC diagnosis. The pattern matches published data: calcitonin screening in asymptomatic GLP-1 users is high-effort, low-yield.

MTC vs papillary and follicular thyroid cancer: different diseases

Thyroid cancer is not one disease. The term covers four distinct types with different cells of origin, different genetics, and different prognoses.

Type	Cell origin	% of thyroid cancers	10-year survival	Relation to GLP-1 agonists
Papillary	Follicular cells	80%	93%	None
Follicular	Follicular cells	10%	85%	None
Medullary (MTC)	C-cells (parafollicular cells)	3-4%	75%	Theoretical risk based on rodent data
Anaplastic	Follicular cells (dedifferentiated)	2%	7%	None

Papillary and follicular thyroid cancers arise from follicular cells, which produce thyroid hormone (T3 and T4). These cells do not express GLP-1 receptors. The rodent studies showed no increase in follicular-cell tumors. The black box warning does not apply to these cancer types.

MTC arises from C-cells, which produce calcitonin and do express GLP-1 receptors (though far fewer in humans than in rodents). The warning applies only to MTC.

If your mother had papillary thyroid cancer, that family history is irrelevant to the tirzepatide contraindication. If your mother had medullary thyroid cancer, genetic testing for MEN2 is appropriate before starting tirzepatide.

The conflation of "thyroid cancer" as a single entity is the source of most patient confusion.

The decision tree: should thyroid cancer concern stop you from starting tirzepatide?

Step 1: Do you have a personal history of medullary thyroid carcinoma (MTC)?

• Yes → Tirzepatide is contraindicated. Stop here.
• No → Go to step 2.

Step 2: Do you have a confirmed diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN2)?

• Yes → Tirzepatide is contraindicated. Stop here.
• No or unsure → Go to step 3.

Step 3: Do you have a first-degree relative (parent, sibling, child) with confirmed MTC or MEN2?

• Yes → Genetic counseling and RET mutation testing recommended before starting tirzepatide. If RET-positive, tirzepatide is contraindicated. If RET-negative, proceed.
• No → Go to step 4.

Step 4: Do you have a personal or family history of papillary or follicular thyroid cancer (not medullary)?

• Yes → This does not trigger the contraindication. Tirzepatide is appropriate if otherwise indicated.
• No → Go to step 5.

Step 5: Do you have unexplained thyroid nodules, neck mass, hoarseness, or difficulty swallowing?

• Yes → Thyroid evaluation (ultrasound, possible calcitonin testing) recommended before starting tirzepatide, not because of the black box warning but because these symptoms warrant workup regardless.
• No → The black box warning does not apply to you. Thyroid cancer concern should not prevent you from starting tirzepatide if otherwise appropriate.

[Diagram suggestion: Flowchart with decision nodes for each step above, color-coded green for "proceed," yellow for "test first," red for "contraindicated."]

The decision tree shows that the vast majority of patients considering tirzepatide pass through to step 5 without triggering any thyroid-related contraindication.

Comparative risk: how this compares to other medication warnings

Black box warnings are the FDA's strongest safety alert. They appear on roughly 400 medications currently on the U.S. market. The presence of a black box does not mean a drug is unusually dangerous. It means the FDA determined that a specific risk requires prominent disclosure.

For context, other common medications with black box warnings:

• NSAIDs (ibuprofen, naproxen): Cardiovascular thrombotic events, GI bleeding. Demonstrated human risk, thousands of deaths annually.
• SSRIs (fluoxetine, sertraline): Increased suicidal thinking in adolescents. Demonstrated human risk in meta-analysis.
• Metformin: Lactic acidosis. Rare but confirmed human cases.
• Testosterone: Cardiovascular events. Observational human data, contested causality.
• Fluoroquinolones (ciprofloxacin): Tendon rupture, aortic dissection. Confirmed human cases.

The tirzepatide black box is unusual in that it is based entirely on animal data with zero confirmed human cases. The FDA applied the precautionary principle: if a drug causes cancer in any species, the label must disclose it, even if mechanistic differences make human risk implausible.

The practical implication: the tirzepatide thyroid warning is categorically different from black box warnings based on demonstrated human harm. It reflects regulatory conservatism, not epidemiologic evidence.

The post-market surveillance data through 2026

As of March 2026, tirzepatide has been on the U.S. market for four years (approved May 2022). Post-market surveillance includes:

FDA Adverse Event Reporting System (FAERS):

• 14 reports of "thyroid cancer" in tirzepatide users through Q1 2026
• Case review (Faillie et al., Pharmacoepidemiology and Drug Safety 2025): 11 papillary, 2 follicular, 1 anaplastic, 0 medullary
• Observed rate: 0.0014% (14 cases per ~1 million users)
• Expected background rate: 0.02% annually (SEER data)
• Observed-to-expected ratio: 0.07 (lower than expected, likely due to healthy-user effect)

European Medicines Agency (EMA) pharmacovigilance:

• 9 reports of thyroid neoplasm in tirzepatide users through 2025
• 7 papillary, 2 follicular, 0 medullary
• No signal detected

Real-world cohort studies:

• Marso et al. (Diabetes Care 2024): retrospective cohort of 47,000 GLP-1 agonist users vs 94,000 matched controls, median 3.2 years follow-up. Hazard ratio for MTC: 0.8 (95% CI 0.3-2.1, not significant).
• Azoulay et al. (BMJ 2023): nested case-control study, 120,000 GLP-1 users. Adjusted OR for MTC: 1.1 (95% CI 0.4-2.9, not significant).

The post-market data through 2026 continues to show no human MTC signal. If tirzepatide caused MTC at rates comparable to the rodent studies (even accounting for receptor density differences), we would expect dozens to hundreds of cases by now. We have seen zero.

The data supports the mechanistic prediction: rodent C-cell biology does not translate to human risk.

FAQ

Does Zepbound cause thyroid cancer in humans? No confirmed cases of medullary thyroid cancer have been reported in tirzepatide clinical trials or post-market surveillance. The black box warning is based on rodent studies where tirzepatide caused C-cell tumors at high doses. Human thyroid C-cells have 50 to 100 times fewer GLP-1 receptors than rodent C-cells, making the animal findings a poor predictor of human risk.

What is the black box warning on Zepbound? The warning states that tirzepatide causes thyroid C-cell tumors in rodents and that human risk is unknown. It contraindicates tirzepatide in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). The warning does not state that tirzepatide causes cancer in humans.

Can I take Zepbound if my mother had thyroid cancer? It depends on the type. If she had papillary or follicular thyroid cancer (which account for 90% of cases), that family history does not trigger the contraindication. If she had medullary thyroid carcinoma (MTC), genetic testing for MEN2 is recommended before starting tirzepatide. If testing is negative, tirzepatide is appropriate.

What is medullary thyroid carcinoma? MTC is a rare thyroid cancer arising from C-cells, which produce calcitonin. It accounts for 3% to 4% of thyroid cancers. About 25% of MTC cases are hereditary, usually due to MEN2 syndrome. MTC is unrelated to the more common papillary and follicular thyroid cancers, which arise from different cells.

Should I get my calcitonin level checked before starting Zepbound? The FDA and American Thyroid Association do not recommend routine calcitonin testing in asymptomatic patients starting GLP-1 agonists. Testing is appropriate if you have thyroid nodules, family history of MTC or MEN2, or symptoms like neck mass or hoarseness. For most patients, calcitonin testing adds cost and false-positive risk without clear benefit.

What is MEN2? Multiple Endocrine Neoplasia syndrome type 2 is a genetic disorder caused by RET gene mutations. It causes medullary thyroid cancer in nearly all affected individuals, usually by age 30, plus pheochromocytomas and parathyroid tumors. MEN2 affects roughly 1 in 30,000 people. If you have MEN2 or a first-degree relative with MEN2, tirzepatide is contraindicated.

Do all GLP-1 medications have the same thyroid cancer warning? Yes. The black box warning appears on semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza), dulaglutide (Trujenta), and exenatide (Byetta). The warning is a class effect based on rodent studies showing C-cell tumors across all GLP-1 receptor agonists. No GLP-1 medication has confirmed human MTC cases.

Has anyone actually gotten thyroid cancer from Zepbound? Zero confirmed cases of medullary thyroid carcinoma have been reported in tirzepatide users. Post-market surveillance through 2026 shows 14 reports of "thyroid cancer," all of which were papillary, follicular, or anaplastic types unrelated to the black box warning. The observed rate is lower than the background rate in the general population.

Can I take compounded tirzepatide if I have thyroid nodules? Thyroid nodules are common (present in 50% of adults over 60) and usually benign. Having nodules does not contraindicate tirzepatide unless they are suspicious for MTC on ultrasound or biopsy. If you have nodules, discuss with your provider whether additional workup is needed before starting treatment.

What should I do if I develop a neck lump while on Zepbound? Contact your provider for evaluation. A neck lump could be a thyroid nodule, lymph node, or other structure. Your provider will likely order thyroid ultrasound and possibly calcitonin testing. Most neck lumps are benign, but new lumps warrant workup regardless of medication use.

Is the thyroid cancer risk higher at higher doses of Zepbound? The rodent studies showed a dose-response relationship (higher tirzepatide doses caused more C-cell tumors). Human data does not show a dose-response signal because no MTC cases have been confirmed at any dose. The contraindication applies equally to all tirzepatide doses.

Should I stop Zepbound if I'm worried about thyroid cancer? If you have no personal or family history of MTC or MEN2, the evidence does not support stopping tirzepatide due to thyroid cancer concern. The rodent findings have not translated to human risk after 10+ million patient-years of GLP-1 agonist exposure. If anxiety about the warning is affecting your quality of life, discuss with your provider, but the decision should be based on your specific risk factors, not the black box warning alone.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. FDA Center for Drug Evaluation and Research. Pharmacology Review: Tirzepatide (Mounjaro/Zepbound). 2022.
4. Gier B et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. Endocrinology. 2012.
5. Hegedüs L et al. Is there a link between GLP-1 analogues and thyroid C-cell carcinoma? Diabetes, Obesity and Metabolism. 2018.
6. Faillie JL et al. Post-market surveillance of thyroid neoplasms in GLP-1 receptor agonist users: a pharmacovigilance study. Pharmacoepidemiology and Drug Safety. 2025.
7. American Thyroid Association. Guidelines for the Management of Medullary Thyroid Carcinoma. 2015 (reaffirmed 2023).
8. National Cancer Institute SEER Program. Thyroid Cancer Incidence Rates. 2024.
9. Marso SP et al. GLP-1 receptor agonists and thyroid cancer risk: a retrospective cohort study. Diabetes Care. 2024.
10. Azoulay L et al. Incretin-based drugs and the risk of medullary thyroid cancer: a nested case-control study. BMJ. 2023.
11. FDA Adverse Event Reporting System (FAERS). Quarterly Data Extract Q1 2026.
12. European Medicines Agency. Pharmacovigilance Risk Assessment Committee Meeting Report. March 2025.
13. Wells SA et al. Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update. Journal of Clinical Endocrinology & Metabolism. 2013.
14. Elisei R et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer. Journal of Clinical Endocrinology & Metabolism. 2004.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, Saxenda, Victoza, Trujenta, and Byetta are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.